Oncolytic Viruses and Cancer Immunotherapy

• Published in: Current oncology reports Vol. 25; no. 1; pp. 19 - 28
• Main Authors: Malhotra, Jyoti, Kim, Edward S.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.01.2023; Springer Nature B.V
• Subjects: Antitumor activity; Antiviral drugs; Cancer immunotherapy; Chemotherapy; Clinical trials; Humans; Immune checkpoint inhibitors; Immune response; Immunotherapy; Lung cancer; Lung Cancer (H Borghaei; Lung Neoplasms - therapy; Medicine; Medicine & Public Health; Neoplasms - therapy; Oncology; Oncolysis; Oncolytic Virotherapy; Oncolytic Viruses - genetics; Section Editor; Topical Collection on Lung Cancer; Toxicity; Treatment Outcome; Tumors; Viruses; Oncolytic viruses; Clinical trials; Immunotherapy combinations
• ISSN: 1523-3790; 1534-6269; 1534-6269
• DOI: 10.1007/s11912-022-01341-w

Purpose of Review Oncolytic viruses (OVs) exert their antitumor effect through selective killing of cancer cells and induction of host anti-tumor immunity. This review aims to summarize the recent and current trials with OVs for the treatment of lung cancer. Recent Findings Several OVs have been developed for the treatment of lung cancer including adenovirus, coxsackievirus B3, reovirus, and vaccinia virus and trials have demonstrated a safe toxicity profile. Early-phase trials in lung cancer with OVs have reported antiviral immune responses and evidence of clinical benefit. However, clinical efficacy of OVs in lung cancer either as monotherapy or in combination with chemotherapy has not been confirmed in larger phase II or III trials. Development of OVs in lung cancer has been limited by difficulty in administering OVs in the tumor directly as well as achieving adequate viral load at all tumor sites with systemically administered OVs. Summary Developing novel combinations with OVs, especially checkpoint inhibitors and other immunotherapeutics, may be a strategy to address the limited success seen thus far. Integrating appropriate biomarker studies and meaningful endpoints in future clinical trials will be imperative. Using novel viral delivery systems in addition to increasing tumor specificity through improved genetic modifications in the OVs are other strategies to improve efficacy.